Catalog ID
PTL-RETA
Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist; weight-management research peptide
Retatrutide, a triple GIP, GLP-1 and glucagon receptor agonist, investigated in appetite regulation, energy expenditure and adiposity research models.
Molecular Formula
C221H342N46O68 (reported)
Formula reported in literature; verify against COA.
Purity
≥98%
Molecular Weight
~4730 g/mol (reported)
Classification
Triple GIP/GLP-1/glucagon receptor agonist
Price
¥159 – ¥55,494 JPY
Indicative range · converted from USD · free shipping from €500
Pricing tiers · mass & purity
1 mg
¥55,494
≥98%
5 mg
¥159
≥98%
10 mg
¥317
≥98%
Scientific Background
Retatrutide is a synthetic triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. It is studied in weight-management research for effects on appetite regulation, energy expenditure and adiposity in preclinical and clinical models. Molecular values are reported in literature and should be verified against the certificate of analysis.
Research Focus — Pathways
GIP, GLP-1 and glucagon receptor signaling; energy-intake and energy-expenditure regulation.
Research Areas
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism
- Energy expenditure
- Adiposity research
Molecular Formula
C221H342N46O68 (reported)
Formula reported in literature; verify against COA.
Molecular Weight
~4730 g/mol (reported)
Amino Acid Sequence
Triple agonist peptide (reported, modified GLP-1/glucagon/GIP hybrid)
Classification
Triple GIP/GLP-1/glucagon receptor agonist
Research Format
Lyophilized research reagent
Purity
≥98%
Peptide Classification
Triple GIP/GLP-1/glucagon receptor agonist
Sequence Notation
Triple agonist peptide (reported, modified GLP-1/glucagon/GIP hybrid)
Scientific References
The following authoritative sources provide peer-reviewed literature on Retatrutide. Peptide Hub Biotech World Wide does not claim these sources endorse this product.
Retatrutide — PubChem compound data
PubChem
https://pubchem.ncbi.nlm.nih.gov/#query=RetatrutideRetatrutide — PubMed literature
PubMed / NCBI
https://pubmed.ncbi.nlm.nih.gov/?term=retatrutide
Retatrutide — frequently asked
What is Retatrutide used for in research?
Retatrutide (Triple GIP/GLP-1/glucagon receptor agonist; weight-management research peptide) is investigated in gip receptor agonism, glp-1 receptor agonism, glucagon receptor agonism, energy expenditure, adiposity research research. Retatrutide is a synthetic triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. It is studied in weight-management research for effects on appetite regulation, energy expenditure and adiposity in preclinical and clinical models. Molecular values are reported in literature and should be verified against the certificate of analysis.
What purity and documentation does Retatrutide include?
Retatrutide is supplied at ≥98% reported purity as a Lyophilized research reagent. A Certificate of Analysis (COA) is available on request with every order.
Does Peptide Hub Biotech World Wide ship Retatrutide to the USA, Canada, Europe, Australia and New Zealand?
Yes. Peptide Hub Biotech World Wide ships Retatrutide to research customers in the United States, Canada, across Europe, Australia, New Zealand and South American markets. Bulk and wholesale quotes are available via the contact form.
How can I order Retatrutide?
Order directly from each product page via our Bitcoin (BTC) checkout — there is no minimum order, and shipping is free on orders from €500 (converted to your local currency). For bulk or wholesale quantities, request a quote through the contact form. After payment, confirm your transaction by email and shipping will proceed.
Related Products
NEWWeight Management≥98%Semaglutide
GLP-1 receptor agonist studied in appetite regulation, energy intake and adiposity research.
NEWWeight Management≥98%Tirzepatide
Dual GIP/GLP-1 receptor agonist studied in appetite regulation and adiposity research.
Metabolic & Endocrine99.2%GLP-1 Receptor Agonists
Glucagon-like peptide-1 receptor agonists studied in metabolic and glucose-regulation research.
QC & Quality Systems
Every lot is verified by HPLC and mass-spectrometry purity analysis, peptide-content determination and residual-solvent testing, with a Certificate of Analysis issued per batch — aligned to ISO 9001:2015 and ISO 13485:2016 quality systems, with FDA Drug Master File (DMF) and MDSAP regulatory pathways supported.
ISO 9001:2015
Quality Management System
ISO 13485:2016
Medical Device QMS
FDA DMF
Drug Master File
MDSAP
Medical Device Single Audit Program
Quality & Documentation
Certificate of Analysis available on request · Research Use Only
Request a Quote